Association between the standardized uptake value and high-risk HPV in hypopharyngeal squamous cell carcinoma. (October 2014)

• Record Type: Journal Article
• Authors: Joo, Young-Hoon; Yoo, Ie-Ryung; Lee, Youn-Soo; Cho, Kwang-Jae; Park, Jun-Ook; Nam, In-Chul; Kim, Chung-Soo; Kim, Sang-Yeon; Kim, Min-Sik
• Is Part Of: Acta oto-laryngologica. Volume 134:Number 10(2014)
• Page Start: 1062
• Page End: 1070
• Publication Date: 2014-10
• Subjects: Otolaryngology -- Periodicals; Ear -- Diseases -- Periodicals; Throat -- Diseases -- Periodicals; Otolaryngology -- Electronic Resources; Otorhinolaryngologic Diseases; 617.8
• DOI: 10.3109/00016489.2014.905701
• Languages: English
• ISSNs: 0001-6489

Abstract

<abstract> <title>Abstract</title> <p> <italic>Conclusion:</italic> Median <sup>18</sup>F-FDG PET/CT maximum standardized uptake values (SUV<sub>max</sub>) cut-off values of 7.9 or greater were associated with high-risk human papillomavirus (HPV) negativity in patients with hypopharyngeal squamous cell carcinoma (HPSCC). Furthermore, median <sup>18</sup>F-FDG PET/CT SUV<sub>max</sub> cut-off values of 7.9 or greater and high-risk HPV negativity were associated with adverse outcomes. <italic>Objectives:</italic> We studied the association and the potential prognostic significance of <sup>18</sup>F-FDG PET/CT and high-risk HPV status in HPSCC. <italic>Methods:</italic> The medical records of 45 patients who underwent <sup>18</sup>F-FDG PET/CT for HPSCC before surgery were reviewed. High-risk HPV in situ hybridization was performed to detect HPV infection. <italic>Results:</italic> The median SUV<sub>max</sub> was 9.91 ± 4.91 (range 1.9–22.1) and the positive rate of high-risk HPV in situ hybridization was 11% (5 of 45). The SUV<sub>max</sub> values of negativity for the high-risk HPV subtypes (10.47 ± 4.87) and positivity (5.48 ± 2.45) were found to be significantly different (<italic>p</italic> = 0.030). The SUV<sub>max</sub> cut-off value for differentiating negativity for the high-risk HPV subtypes from positivity was 7.9, with a sensitivity of 65% and a specificity of 80%. The 5-year disease-specific survival rate (DSSR) in our cohort was 57%. Patients with an SUV<sub>max</sub> value higher than 7.9 (<italic>p</italic> = 0.005) and high-risk HPV negativity (<italic>p</italic> = 0.047) had decreased 5-year DSSR.</p> </abstract>